secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2025-02-12T23:59:59+00:00
Accession:  0001437749-25-003563
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma reports Q2 net income $0.8M; Pediatric revenue up 86% sequentially
--------------------------------------------------------------------------------

- Net revenue $16.2M, down 13% YoY; ADHD revenue fell 17% to $13.8M, Pediatric rose 12% to $2.4M.
- Net income $0.8M ($0.13 basic EPS) vs net loss $0.2M in Q2FY24; adjusted EBITDA $1.3M vs $5.5M.
- Sequential prescription growth for both ADHD and Pediatric portfolios, first since Q2FY23.
- Cash $20.4M at Dec 31, 2024, flat vs Sep 30; cost savings initiatives to cut at least $2M annually.
- Gross margin 66% vs 78% a year ago due to higher-cost ADHD inventory from manufacturing transition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000143774925003563/0001437749-25-003563-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000143774925003563/aytu20241121_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-003563

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer